WuXi STA Changzhou site passes first US FDA inspection

摘要

China's contract development and manufacturing firm, STA Pharmaceutical Co. Ltd., (WuXi STA), a subsidiary of WuXi AppTec, announced that its active pharmaceutical ingredient (API) R&D and manufacturing facility located in Changzhou, China has secured Pre-Ap-Proval Inspection (PAI) for two APIs from the US Food and Drug Administra- tion (FDA) - with no Form 483s issued.